We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Drug Sponsors Must Repeat Studies Done by Two Indian CROs, FDA Says
Drug Sponsors Must Repeat Studies Done by Two Indian CROs, FDA Says
In a rare move, the FDA has informed multiple drug sponsors that used two Indian contract research organizations (CROs) with concerning data integrity practices that the bioequivalence or bioavailability studies those firms conducted will need to be repeated elsewhere.